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IN PRACTICE

CASE REPORT

A case of refractory thrombotic thrombocytopenic
purpura treated with plasmapheresis and rituximab
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Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder with no prevalence or incidence studies in sub-Saharan
Africa. Acquired TTP has several causes, all of which lead to decreased activity of von Willebrand factor cleaving protease (ADAMTS13)
due to autoantibodies that are directed towards ADAMTS13. We report a case of a 46-year-old man who presented with most of the classic
clinical manifestations of TTP.
S Afr Med J 2016;106(7):689-691. DOI:10.7196/SAMJ.2016.v106i7.9856

Background

Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threaten
ing disorder that occurs due to deficiency of ADAMTS13 (a disintegrin
and metalloproteinase with a thrombospondin type 1 motif, member
13), which is a von Willebrand factor (VWF) cleaving protein.[1]
The absent or severely reduced activity of ADAMTS13 in patients
with TTP prevents timely cleavage of unusually large multimers of
VWF as they are secreted by endothelial cells, resulting in adhesion
and aggregation of platelets in flowing blood, with formation of
microvascular thrombi, which are responsible for most of the clinical
features.[2] Both congenital and acquired forms of TTP have been
described. There are no prevalence or incidence studies on TTP in
sub-Saharan Africa (SSA), but several case reports are available in
literature. Scully et al.[3] in the UK reported a TTP incidence rate of
six cases per million people in 2008.
There are several causes of acquired TTP, all of which lead to
decreased activity of ADAMTS13 due to autoantibodies that are
directed towards ADAMTS13.[4] The classic presentation of TTP
is that which follows postinfectious intestinal infection with either
shigatoxin-producing Escherichia coli or Shigella dysenteriae.[5] HIV
infection has been directly associated with TTP,[6] and a case series
by Gunther et al.,[7] in South Africa in 2007, demonstrated that HIVassociated TTP was the most common form of TTP. Postinfectious
TTP is therefore the most common cause of TTP in SSA, where there
is still a high incidence of infectious diseases.
TTP was originally characterised by a pentad of thrombocytopenia,
microangiopathic haemolytic anaemia, fluctuating neurological deficits,
renal impairment and fever, often with insidious onset.[8] However,
TTP can present without the full pentad. Up to 35% of patients do not
have neurological signs at presentation, and renal abnormalities and
fever are not always prominent features.[9] Galbusera et al.[9] in 2006
described revised diagnostic criteria for TTP in which the diagnosis can
be made upon identification of the presence of thrombocytopenia and
microangiopathic haemolytic anaemia (MAHA) only. Other atypical
manifestations of TTP that have been described include non-occlusive
mesenteric ischaemia, pancreatitis, hepatitis, acute respiratory distress
syndrome and peripheral digital ischaemia.[10,11]
TTP is a severe illness and, if untreated, >90% of patients die from
the syndrome.[12] Plasmapheresis is the treatment of choice for TTP,
in addition to steroids, which are initiated immediately after start of
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plasma exchange therapy (PEX).[8] Rituximab is effective and safe
in acute idiopathic TTP and in patients with immune TTP who
have failed to respond to PEX and steroids.[13] The poor outcome of
untreated patients is a big challenge particularly in SSA, where there
are poor health systems and poor access to quality healthcare.
We report a case of a 46-year-old man who presented with most of
the classic clinical manifestations TTP.

Case presentation

A 46-year-old male patient born deaf and dumb presented to the Aga
Khan University Hospital as a referral from a peripheral facility, with
a 2-week history of severe headache, abdominal pains, diarrhoea
and vomiting. He had been fine prior to the onset of symptoms
and there was no history of travel to a malaria endemic region. The
headache was occipital, of sudden onset, severe (scale 8 - 10/10), nonradiating, worsened with activity and was temporarily relieved by
use of analgesics. There was no associated fever or neck stiffness. He
had visual hallucinations with no other visual symptoms. Diarrhoea
was watery and not blood stained, and the vomiting was mostly
postprandial with associated epigastric abdominal pain. There was
no history of decreased urine output, lower-limb swelling and facial
swelling, and no respiratory symptoms. His past medical history
and family history were non-significant. He worked as a tailor and
was married with three children. Physical examination showed a
well-developed, middle-aged black African male patient of good
nutritional status and with stable vital signs. He had mild pallor, was
not jaundiced, had no lymphadenopathy and no oedema, and skin
examination was normal. He communicated by sign language, his
neck was supple and the rest of the neurological examination findings
were unremarkable. Abdominal, respiratory and cardiovascular
examinations were unremarkable. Laboratory findings showed severe
anaemia (haemoglobin 5.8 mg/dL), thrombocytopenia (platelet
counts 9 × 109), increased lactate dehydrogenase activity (517 IU/L)
and schistocyte count was 3%. Renal and liver function tests were
normal with a negative direct Coombs test. HIV antibody, hepatitis B
surface antigen and hepatitis C virus antibody tests were negative.
Blood and stool cultures were negative, while renal and liver function
tests were normal; it is important to note that he had been on
intravenous antibiotics in the referring facility. His blood slide for
malaria parasites was also negative.
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TTP was suspected because of the haemolytic
anaemia, thrombocytopenia, schistocytes on
the peripheral blood film and the neurological
manifestations. The patient was started on PEX
at a dose of one volume PEX daily, and the
efficacy of the plasma exchange was monitored
using daily thrombocyte levels. Despite being
on daily PEX, his thrombocytes did not
improve until after 5 days of therapy. After
1 week in the hospital, undergoing PEX, he
was noted to have declining mental status, and
increased aggressiveness and disorientation.
Magnetic resonance imaging was not done
because of the need for sedation. Computed
tomography scan of the brain showed small
bilateral subdural haematomas with no pressure
effects; the patient was put on conservative
management with continued monitoring of
neurological status. He improved and there
was no need for neurosurgical intervention.
After seven sessions of PEX, the thrombo
cytes improved to 157 × 109/L. PEX was
stopped after the thrombocyte levels
remained above 150 × 109/L for 2 consecutive days. Three days after PEX had been
stopped, the thrombocytes dropped to 47 ×
109/L, and a diagnosis of refractory TTP was
made. Finan
cial constraints limited subsequent PEX to one more session, and only one
dose of rituximab (375 mg/m2 body weight)
for refractory TTP was given. The thrombocytes improved and the patient’s clinical
condition improved tremendously, and he
was discharged 4 days after the dose of rituximab. The thrombocyte count improved to
160 × 109/L on starting rituximab and to
198 × 109/L on review in a clinic 2 weeks later.
The patient was discharged on prednisolone,
tapered over 3 months. He was doing very
well 3 months post discharge, with no symptoms, and he had returned to work. He had a
platelet count of 253 × 109/L and 233 × 109/L
on review 2 and 3 months post discharge,
respectively (Fig. 1).

Discussion

TTP was diagnosed in this patient owing to
the presence of thrombocytopenia, MAHA
with schistocytes of 3% and neurological
manifestations.[9] Systemic bacterial and
fungal infections were excluded with several
negative blood cultures, as severe sepsis is
one of the differentials for schistocytosis and
thrombocytopenia.[14] Patients with severe
sepsis may also present with disseminated
intravascular coagulation with a subsequent
lack of procoagulant proteins, causing
bleeding diathesis and anaemia.
TTP is a life-threatening condition, espe
cially in SSA, where optimal treatment
facilities are not available. PEX was initiated
owing to a presumptive diagnosis of TTP
because of the associated high mortality of
up to 90% in untreated patients.[12] PEX is the
mainstay of treatment in TTP as it reduces
mortality from 90% to 10 - 20%.[8] This
modality of treatment depletes the circulating
antibodies against ADAMTS13 and the very
high molecular weight von Willebrand
factor multimers. PEX also replaces the
missing von Willebrand cleaving protease. [15]
Although the mortality of TTP has been
reduced in most European countries and
in America, we postulate that TTP still has
a high mortality in SSA owing to lack of
PEX. Management of refractory TTP is a
bigger challenge owing to the need for more
prolonged duration of treatment. However,
more intensive PEX may be required in
resis
tant cases with new-onset symptoms
while on therapy.[16] Our patient improved
tremendously but deteriorated 2 days postPEX, with thrombocytes dropping to 47.
Owing to financial constraints, only one
additional session of PEX was done for
refractory TTP and one dose of rituximab
was given. Fakhouri et al.[13] showed that
rituximab is effective and safe in immune
TTP for patients who have failed PEX and
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Fig. 1. Platelet counts against intervention. (R = rituximab; wk = weeks; mo = months.)
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methylprednisone treatment and in acute
relapsed TTP. Rituximab is the current
treatment of choice for refractory TTP and
should be given once weekly for 4 weeks;[3,8]
our patient was started on rituximab early
because of the challenges of PEX in our
setting. Rituximab in combination with
prednisone is effective and can be used with
out concurrent plasma exchange in patients
without neurological or renal impairment. [17]
Long-term consequences of TTP are not
well known, but it has been postulated that
some patients may go on to develop longterm renal dysfunction and neurocognitive
deficits.[15]
This case report demonstrates both the
poss
ibilities and challenges of managing
TTP. Diagnosis and initiation of appropriate
therapy according to international guidelines
was possible for this patient and a relatively
good response was demonstrated. However,
our patient did not receive optimal care
owing to financial constraints; this is
a common scenario in SSA. Our patient
responded well to one dose of rituximab.
Further studies are necessary to explore the
viability of use of rituximab alone in settings
where PEX is not possible.

Conclusions

TTP can present without the full pentad
of the classic clinical presentation. There
should be increased suspicion of TTP in
patients who present with MAHA, especially
in a population that has a high prevalence
of HIV infection. This is the first reported
case of TTP that was relatively appropriately
managed with plasma exchange and rituxi
mab in this part of the developing world.
Rituximab has been used for patients with
resistant and relapsed TTP with successful
results in other regions of the world; these
results can be replicated in our setting.
Further studies to assess the feasibility
and viability of the use of rituximab alone
in settings where PEX is not possible are
necessary.
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